Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Average Recommendation of “Buy” from Brokerages

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) have earned a consensus recommendation of “Buy” from the twelve research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, nine have given a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $22.90.

A number of analysts recently weighed in on TRVI shares. Wall Street Zen cut shares of Trevi Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Stifel Nicolaus set a $30.00 price target on shares of Trevi Therapeutics in a research note on Friday, May 8th. Needham & Company LLC reiterated a “buy” rating and set a $23.00 price target on shares of Trevi Therapeutics in a research note on Wednesday, May 20th. JonesTrading decreased their price target on shares of Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research note on Thursday, March 19th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Trevi Therapeutics in a research note on Monday, April 20th.

Institutional Trading of Trevi Therapeutics

Hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. lifted its stake in shares of Trevi Therapeutics by 194.5% in the 2nd quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company’s stock worth $25,000 after acquiring an additional 2,996 shares during the period. KBC Group NV acquired a new stake in shares of Trevi Therapeutics in the 1st quarter worth $29,000. Hilton Head Capital Partners LLC acquired a new stake in shares of Trevi Therapeutics in the 4th quarter worth $40,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Trevi Therapeutics in the 4th quarter worth $50,000. Finally, Strs Ohio acquired a new stake in shares of Trevi Therapeutics in the 1st quarter worth $52,000. Institutional investors and hedge funds own 95.76% of the company’s stock.

Trevi Therapeutics Price Performance

Shares of NASDAQ:TRVI opened at $13.40 on Thursday. The stock has a market cap of $1.90 billion, a P/E ratio of -41.88 and a beta of 1.04. The firm has a fifty day moving average price of $13.88 and a 200 day moving average price of $12.46. Trevi Therapeutics has a 1-year low of $5.41 and a 1-year high of $16.12.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02). Sell-side analysts expect that Trevi Therapeutics will post -0.47 EPS for the current fiscal year.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.